Proctitis News and Research

RSS

Sixteen countries reported monkeypox virus infection in humans between April and June 2022

Researchers have analyzed the recent cases related to the monkeypox virus infection.

27 Jul 2022

Researchers describe viral shedding of monkeypox virus in patients to better understand the possible role of different bodily fluids in disease transmission

Researchers described the shedding of the monkeypox (MPX) virus (MPXV) in Barcelona city of Spain.

20 Jul 2022

CDC experts update on monkeypox in the United States

Scientists working with the CDC provide the latest information about monkeypox in the U.S.

19 Jul 2022

PENTAX Medical introduces new electrosurgical and argon plasma coagulation platforms

PENTAX Medical announces the addition of new dedicated electrosurgical and argon plasma coagulation platforms – the ENDO ARC and ENDO PLUS – to its therapeutic accessories range.

From PENTAX Medical Company 21 Feb 2019

AGA's new clinical guideline to help manage patients with mild-to-moderate ulcerative colitis

Most patients with ulcerative colitis have mild-to-moderate disease characterized by periods of activity or remission, but practice variations exist in disease management.

10 Jan 2019

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1

21 Feb 2014

Scientists discover 12 genetic markers for ED in prostate cancer patients after radiotherapy

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.

27 Sep 2012

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including a long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile Infection that included 77 patients from five different states-- unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

IMRT minimizes gastrointestinal side effects of prostate cancer treatment

Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Meda signs agreement to acquire Alaven

Meda has signed an agreement to acquire the US specialty pharmaceutical company Alaven. The acquisition will significantly enhance Meda's marketing capabilities in the US and expand the therapeutic focus to include both gastroenterology and women's health; areas that Meda already operates in outside of the US.

30 Aug 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Asacol treats UC symptoms of isolated proctitis

Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.

5 Dec 2007

First UK cases of previously rare disease reported in gay men

A previously rare disease has been reported for the first time in the UK, Lymphograunuloma venereum (LGV) is a genital/anogenital bacterial infection caused by a particularly invasive strain of Chlamydia trachomatis.

3 Apr 2005